An Open-label, Multicenter, Dose-escalation and Cohort Expansion Phase 1 Clinical Study of ES102 in Combination With JS001 in Patients With Advanced Solid Tumors
Latest Information Update: 21 Apr 2023
At a glance
- Drugs INBRX 106 (Primary) ; Toripalimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Elpiscience Biopharmaceuticals
- 18 Apr 2023 Planned number of patients changed from 106 to 82.
- 20 Oct 2022 Planned number of patients changed from 146 to 106.
- 28 Oct 2021 Status changed from not yet recruiting to recruiting.